Vensana Capital Strengthens Team with Key Appointments to Drive MedTech Innovation

The recent appointments of Maria Berkman, MD, as Partner and Ross (Rusty) Segan, MD, as Venture Partner at Vensana Capital mark a significant step in the firm's mission to foster innovation in the medical technology sector. These strategic hires bring a wealth of experience and a proven track record in medtech investments and healthcare innovation, positioning Vensana Capital to further its impact on the industry.

Maria Berkman's extensive background in venture capital, particularly in early-stage investments in cardiovascular disease and stroke, complements Vensana's focus on breakthrough medical technologies. Her role in launching and managing successful medtech companies, along with her clinical and business acumen, will be invaluable in identifying and nurturing the next generation of healthcare innovations.

Ross (Rusty) Segan's appointment brings over 25 years of global medtech leadership and FDA experience to Vensana. His expertise in product evaluation and quality, combined with his clinical and executive roles in leading medical device companies, underscores the firm's commitment to advancing patient care through cutting-edge technologies. Segan's insights into regulatory and clinical strategies will be crucial for Vensana's portfolio companies navigating the complex healthcare landscape.

These appointments reflect Vensana Capital's dedication to building a team with deep sector expertise to support entrepreneurs in transforming healthcare. The addition of Berkman and Segan not only strengthens the firm's investment strategy but also enhances its ability to drive meaningful advancements in medical technology. For the medtech industry, this signals a continued focus on innovation and collaboration to address unmet medical needs and improve patient outcomes worldwide.